[go: up one dir, main page]

MX2017010631A - Composiciones de dialquil sulfosuccinato, metodos para hacerlas y metodos de uso. - Google Patents

Composiciones de dialquil sulfosuccinato, metodos para hacerlas y metodos de uso.

Info

Publication number
MX2017010631A
MX2017010631A MX2017010631A MX2017010631A MX2017010631A MX 2017010631 A MX2017010631 A MX 2017010631A MX 2017010631 A MX2017010631 A MX 2017010631A MX 2017010631 A MX2017010631 A MX 2017010631A MX 2017010631 A MX2017010631 A MX 2017010631A
Authority
MX
Mexico
Prior art keywords
water
copolymer
dialkyl sulfosuccinate
homopolymer
soluble
Prior art date
Application number
MX2017010631A
Other languages
English (en)
Other versions
MX369634B (es
Inventor
Rischer Matthias
Saly Eric
Mackay Maureen
Mohr Wolfgang
KURZ Lena
Original Assignee
Cytec Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytec Ind Inc filed Critical Cytec Ind Inc
Publication of MX2017010631A publication Critical patent/MX2017010631A/es
Publication of MX369634B publication Critical patent/MX369634B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Una composición sólida de partículas comprende una mezcla de sulfosuccinato de dialquilo y un polímero hidrosoluble puede ser un éter de celulosa, un polisacárido, un homopolímero o copolímero de alcohol polivinílico, un homopolímero o copolímero de polivinilpirrolidona, un polímero o copolímero de polivinilcaprolactama, un poli(met)acrilato, un copolímero de injerto de poli(óxido de alquileno) o una combinación de estos. La composición sólida de partículas fluye libremente, es hidrosoluble y se disuelve rápidamente en agua. Se puede preparar secando una solución de sulfosuccinato de dialquilo y un polímero hidrosoluble. La composición sólida de partículas se puede mezclar con sustancias orgánicas que tienen una solubilidad baja en agua, por ejemplo, un genérico, un agente biológico, un biosimilar, un excipiente, un nutracéutico, un agente de diagnóstico médico, un producto químico agrícola o una combinación de estos, para formar composiciones hidrosolubles.
MX2017010631A 2015-02-20 2016-02-18 Composiciones de dialquil sulfosuccinato, metodos para hacerlas y metodos de uso. MX369634B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562118786P 2015-02-20 2015-02-20
US201662287198P 2016-01-26 2016-01-26
PCT/US2016/018428 WO2016134121A1 (en) 2015-02-20 2016-02-18 Dialkyl sulfosuccinate compositions, method of making, and method of use

Publications (2)

Publication Number Publication Date
MX2017010631A true MX2017010631A (es) 2017-12-04
MX369634B MX369634B (es) 2019-11-14

Family

ID=55442903

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010631A MX369634B (es) 2015-02-20 2016-02-18 Composiciones de dialquil sulfosuccinato, metodos para hacerlas y metodos de uso.

Country Status (6)

Country Link
US (2) US10022328B2 (es)
EP (1) EP3258918A1 (es)
JP (1) JP2018507209A (es)
BR (1) BR112017016657A2 (es)
MX (1) MX369634B (es)
WO (1) WO2016134121A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017016657A2 (pt) * 2015-02-20 2018-04-10 Cytec Ind Inc composições de sulfossuccinato de dialquila, método de feitura, e método de uso
EP4255495A4 (en) 2020-12-03 2025-10-08 Battelle Memorial Institute COMPOSITIONS OF POLYMERIC NANOPARTICLES AND DNA NANOSTRUCTURES AND METHODS FOR NON-VIRAL DELIVERY
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US224163A (en) * 1880-02-03 Bird-cage
US2028091A (en) 1933-07-28 1936-01-14 American Cyanamid & Chem Corp Esters of sulphodicarboxylic acids
NL62992C (es) * 1946-05-27
BE759520A (fr) * 1969-11-28 1971-04-30 Aspro Nicholas Ltd Compositions d'aspirine
JPH02255613A (ja) * 1989-03-27 1990-10-16 Lion Corp ジオクチルソジウムスルホサクシネート配合製剤
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE4139963A1 (de) 1991-12-04 1993-06-09 Basf Ag, 6700 Ludwigshafen, De Redispergierbares dispersionspulver aus n-vinylpyrrolidon-vinylacetat-copolymerisat, dessen herstellung und verwendung
US5834565A (en) 1996-11-12 1998-11-10 General Electric Company Curable polyphenylene ether-thermosetting resin composition and process
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
ATE419834T1 (de) 2000-11-20 2009-01-15 Elan Pharma Int Ltd Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren
WO2004024138A1 (ja) * 2002-09-10 2004-03-25 Taisho Pharmaceutical Co.,Ltd. ジオクチルソジウムスルホサクシネート配合固形製剤
JP2004131393A (ja) * 2002-10-08 2004-04-30 Kowa Co 易溶出性製剤
EA200870368A1 (ru) * 2006-03-24 2009-04-28 Панацея Биотек Лтд. Антибиотические композиции с модифицированным высвобождением и способ их получения
CA2680680A1 (en) 2007-03-29 2009-02-19 Panacea Biotec Limited Modified dosage forms of tacrolimus
US20110082161A1 (en) * 2008-06-30 2011-04-07 Lieven Elvire Colette Baert Powders for reconstitution
JP5135091B2 (ja) * 2008-07-08 2013-01-30 株式会社シマノ 両軸受リールのドラグ調整機構
BR112017016657A2 (pt) * 2015-02-20 2018-04-10 Cytec Ind Inc composições de sulfossuccinato de dialquila, método de feitura, e método de uso

Also Published As

Publication number Publication date
US20160317445A1 (en) 2016-11-03
JP2018507209A (ja) 2018-03-15
WO2016134121A1 (en) 2016-08-25
MX369634B (es) 2019-11-14
BR112017016657A2 (pt) 2018-04-10
EP3258918A1 (en) 2017-12-27
US10022328B2 (en) 2018-07-17
US20180303756A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
MX2017010631A (es) Composiciones de dialquil sulfosuccinato, metodos para hacerlas y metodos de uso.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
BR112016013684A2 (pt) Solução aquosa ou hidrocoloide, método para aumentar a viscosidade de uma composição e método para o tratamento de um material
AT515178A5 (de) Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie
MY190392A (en) A delayed release drug formulation
WO2013052958A3 (en) Antimicrobial compositions and methods employing same
AR063596A1 (es) Composiciones de champu acondicionadoras
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
CL2018000810A1 (es) Composiciones de poliolefina con mejoradas propiedades mecánicas y de barrera
MX2017000341A (es) Resina absorbente al agua y articulo absorbente.
CO6331351A2 (es) Formulaciones que contienen celulosa bacteriana que carecen de un componente de carboximetilcelulosa.
WO2014152782A3 (en) Substantially surfactant-free, submicron dispersions of hydrophobic agents containing high levels of water miscible solvent
CL2009001215A1 (es) Composiciones farmaceuticas que comprenden un primer agente seleccionado del grupo consistente de i) un agente antiinflamatorio, ii) acetaminofeno, iii) fenacetina, iv) tramadol, y un segundo agente; uso de dichas composiciones para tratar enfermedades proliferativas incluyendo cancer.
CR20120140A (es) Composiciones de liberación controlada
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
MX2017009482A (es) Formulación farmacéutica.
BR112013007740A2 (pt) métodos para processamento de microesferas, microesferas processadas por tais métodos e seus usos
MX382580B (es) Formulaciones de liberación inmediata disuasivas de abuso que comprenden polisacáridos no celulósicos.
CR20110226A (es) Composición para tratar enfermedad
MX382596B (es) Composiciones que contienen arsénico y su uso en métodos de tratamiento.
BR112021017878A2 (pt) Carbonato de magnésio com superfície reagida, sistema de liberação, formulação de cuidados domiciliares, métodos para preparar um carbonato de magnésio com superfície reagida e para preparar um sistema de liberação, e, uso de um carbonato de magnésio com superfície reagida e de um sistema de liberação
EP4279137A3 (en) Oral pharmaceutical composition and method for producing particulate formulation comprising composition
BR112015020089A2 (pt) Formulação aquosa de tratamento de semente, formulação pesticida aquosa, e, método para preparar uma formulação
NI201100119A (es) Composición de liberación pulsatil de sildenafil y proceso para prepararla.

Legal Events

Date Code Title Description
FG Grant or registration